Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penetration of Brimonidine in Human Vitreous After Ailamide Instillation
jRCTs051200089Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Ailamide in chorioretinal scar and Full Thickness Macular Hole (FTMH), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoints: Primary: Brimonidine concentration in aqueous humor and Primary: Brimonidine concentration in vitreous body. Started Nov 2020; status: completed.
02
Drugs
Ailamide
03
Conditions
chorioretinal scarFull Thickness Macular Hole (FTMH)
Beyond the preview
Go deeper on jRCTs051200089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200089.